Sinovac receives big boost from Pfizer, AstraZeneca or J&J COVID shootings
[ad_1]
(Reuters) – A third booster dose of COVID-19 vaccine from AstraZeneca (NASDAQ :), Pfizer-BioNTech or Johnson & Johnson (NYSE 🙂 significantly increases antibody levels .
The study found that CoronaVac received the biggest boost from a viral vector or RNA shot, including against Delta and Omicron coronavirus variants, researchers at Brazil and Oxford University said on Monday.
The China-based Sinovac vaccine uses an inactivated version of a coronavirus strain that was isolated from a patient in China. It is currently accepted in more than 50 countries, including Brazil, China, Argentina, South Africa, Oman, Malaysia, Indonesia and Turkey.
“This research provides important opportunities for policy makers in many countries where inactivated vaccines have been used,” said Andrew Pollard, director and head of research at the Oxford Vaccine Group.
However, another study in December found that a two-dose shot of Sinovac showed that a booster dose of the Pfizer-BioNTech vaccine showed a lower immune response to the Omicron variant compared to other strains.
Viral vector vaccines developed by AstraZeneca-Oxford and J&J use a weakened version of another virus to provide genetic guidance for making proteins from a virus that seeks protection. Pfizer (NYSE 🙂 and BioNTech’s mRNA vaccines provide a genetic transcript with instructions for making viral proteins to teach the body how to defend against infections.
A third dose of CoronaVac also increased antibodies, but the results were better when another vaccine was used, according to a recent study that included 1,240 volunteers from the Brazilian cities of Sao Paulo and Salvador.
Antibody levels were low before the booster dose, with only 20.4% of adults aged 18-60 and 8.9% of adults over 60 having perceptible levels of neutralizing antibodies. According to a study published in the medical journal Lancet on Friday, it was seen that they were increasing significantly in all regimens of booster vaccines.
Fusion Media or anyone involved with Fusion Media will not be held liable for any loss or damage as a result of relying on the information contained in the data, estimates, charts and buy / sell signals contained in this website. Please be informed that one of the most risky forms of investment possible is the full information on the risks and costs associated with trading in the financial markets.
[ad_2]
Source link
